Celltrion’s Herzuma Wins Fifth Consecutive Supply Contract in Brazil

Celltrion Inc., South Korea’s largest biosimilar maker, has announced that its breast and stomach cancer treatment “Herzuma” (active ingredient: trastuzumab) has secured a supply contract from Brazil’s federal government for the fifth consecutive year.

This contract will see Celltrion’s Brazilian subsidiary supply 660,000 vials of Herzuma to the federal government until next year.

According to Celltrion, its local network and stable supply chain, established through its Brazilian subsidiary, were key factors in securing this contract.

In addition to the Herzuma contract, Celltrion has also agreed to supply an additional 90,000 vials of the autoimmune disease treatment “Remsima” (active ingredient: infliximab) this year, at the request of the Brazilian federal government.

“We will focus on confirming the dominance of existing products such as Herzuma in the market, while continuing to achieve results with follow-on products such as Vegzelma, which are due to be launched in the second half of this year,” said Kang Kyung-Doo, head of the Latin America division at Celltrion.

Celltrion’s Commitment to Latin America

Celltrion’s success in securing the Herzuma contract highlights the company’s commitment to the Latin American market. With a strong local network and stable supply chain, Celltrion is well-positioned to continue providing high-quality biosimilar treatments to patients in the region.

About Celltrion

Celltrion Inc. is South Korea’s largest biosimilar maker, specializing in the development and manufacture of biosimilar treatments for a range of diseases, including cancer and autoimmune disorders.